-
-
Login
Novo Nordisk is adopting the shorter name ‘Novo’ as part of a major global rebrand. Behind the new logo is a wider shift in how one of diabetes’s oldest companies sees healthcare, patients and an increasingly consumer-driven market.
NICE has backed once-weekly insulin efsitora alfa, branded Onswik, for type 2 diabetes manangement. It could mean 313 fewer basal injections a year, fewer needles and less pressure on injection sites, while delivering glucose control comparable with daily insulin.
A newly published correspondence in The Lancet Diabetes & Endocrinology has now reopened a debate that many healthcare systems believed had largely been settled: does wider CGM adoption always represent good value?
Teplizumab becomes the first NHS-approved treatment shown to delay the onset of type 1 diabetes. Given as a 14-day course of infusions before symptoms develop, the drug could postpone diagnosis by around two to three years and may signal the beginning of a new era in type 1 diabetes treatment.
